Prostate adenocarcinoma

This phase 2 trial tests a combination of a vaccine (TriAdeno) and an immune-boosting drug (N-803) in 52 men with early-stage, low- or medium-risk prostate cancer who are currently on active surveillance. The vaccine targets three proteins found in prostate cancer cells, while N-…

This study tests a personalized radiation approach for men whose prostate cancer has returned after surgery. Using PSMA PET scans, doctors will give higher radiation doses to active cancer spots and lower doses to healthy areas, all in just 5 treatments over two weeks. The goal i…

This study tests whether the drug rezvilutamide, combined with standard hormone therapy, can prevent high-risk prostate cancer from coming back after surgical removal. About 33 participants will take the pills and get injections for up to 2 years. The main goal is to see how many…

This study tests whether using PSMA-PET scans to guide radiation therapy can improve cancer control in men with high-risk prostate cancer that hasn't spread to lymph nodes. About 250 participants will receive radiation to the prostate and nearby tissues, with or without whole pel…

This phase 2 trial tests whether adding darolutamide (a pill that blocks male hormones) to standard hormone therapy after prostate removal can keep cancer from coming back in high-risk patients. About 40 men will take the combination for 12 months and be followed for 2 years. The…

This trial tests a new imaging system that combines PSMA-PET, MRI, and ultrasound to guide robot-assisted prostate surgery. The goal is to help surgeons remove all cancer while sparing healthy tissue, nerves, and urinary control. About 98 men with prostate cancer will take part t…

This study looks at giving the drug rezvilutamide to men with high-risk or locally advanced prostate cancer before their surgery. The goal is to see if it can completely clear cancer cells from the removed tissue and reduce the chance of the cancer coming back. About 115 particip…

This study compares a precise, focused radiation treatment (stereotactic body radiotherapy) to simply watching the cancer (active surveillance) in men with low-to-intermediate risk prostate cancer. The goal is to see if the radiation can reduce the number of men who later need st…

This phase 2 trial tests whether a new radioactive imaging agent, 61Cu-NU101, can detect prostate cancer spread as well as or better than the current standard, Pylarify. 34 men with confirmed prostate cancer and visible disease on a prior Pylarify scan will receive one dose of 61…

This phase 2 trial will test whether a special PET scan using Flotufolastat F18 can accurately detect any remaining prostate cancer after focal therapy (like cryotherapy or HIFU). About 60 men with prostate cancer who haven't had prior treatment will get the scan before and after…

This study tests whether adding telehealth sex therapy to standard pelvic floor physical therapy helps men recover urinary and sexual function after prostate cancer treatment. All participants receive pelvic floor therapy and education on using a vacuum erection device. Half are …

This study tests whether adding estrogen to standard prostate cancer treatment can improve quality of life for 60 men with metastatic hormone-sensitive prostate cancer. Standard therapy often causes hot flashes and other side effects by lowering estrogen. The study compares estro…

This study compares two types of radiation therapy for prostate cancer: one that boosts the whole prostate gland and one that boosts only the main tumor. About 186 men will be randomly assigned to one of the two treatments. The goal is to see which approach causes fewer urinary a…

This study tests whether a procedure called prostate artery embolization (PAE) can reduce urinary side effects from radiotherapy in men with prostate cancer. Participants have large prostates or existing urinary symptoms. They will receive PAE before starting radiation, and resea…

This study compares the side effects of two radiation treatments for men with low-to-intermediate risk prostate cancer: low dose rate brachytherapy (radioactive seeds placed in the prostate) and ultra-hypofractionated radiotherapy (5 sessions of external radiation over 2 weeks). …

Researchers at Anhui Medical University are studying bacteria found inside prostate tumors and how they relate to the immune system. The study uses leftover tissue samples and archived slides from about 100 men with prostate cancer or benign prostate disease. Scientists will sequ…

Researchers at Anhui Medical University are studying how prostate cancer invades nerves, a feature linked to aggressive tumors and recurrence after surgery. They plan to collect tissue and clinical data from about 120 prostate cancer patients and compare nerve-invaded areas, ordi…

This study tests whether injecting a radioactive tracer directly into the prostate artery improves imaging compared to standard arm injection in 10 men with high-risk prostate cancer. The goal is to see if this method gives clearer pictures and helps predict the right radiation d…

This observational study will measure how well the body breaks down blood clots in 150 cancer patients (with blood cancers or solid tumors) who also have clotting issues. Researchers will take extra blood samples during routine care to look for markers that might predict bleeding…